AVS 2211 Midterm 2 Comprehensive Study Guide: Psychopharmacology, Stimulants, Depressants, and Substances of Abuse

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/54

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering psychopharmacology, neurobiology, clinical actions, and side effects of stimulants (cocaine, amphetamines, cathinones), CNS depressants, antipsychotics, antidepressants, alcohol, nicotine, and xanthines.

55 Terms

1
New cards

Cocaine (Origin and Traditional Route)

A natural alkaloid derived from the leaves of the erythroxylon coca plant native to the Andes mountains in Bolivia and Peru, historically administered by chewing leaves held in the cheek to enhance energy.

2
New cards

Coca Paste

A crude, impure extract produced by soaking, mixing, and mashing coca leaves with an organic solvent like kerosene or gasoline, from which excess liquid is filtered out before further processing.

3
New cards

Cocaine Hydrochloride

The stable, water-soluble salt form of cocaine created from coca paste that can be snorted intranasally or dissolved in liquid for intravenous injection, but cannot be heated and smoked without decomposing.

4
New cards

Freebasing

A technique to produce smokable cocaine in which the hydrochloride salt is chemically removed using a volatile, highly flammable organic solvent (such as ether) to yield the pure cocaine base.

5
New cards

Crack Cocaine

A smokable form of cocaine produced by combining cocaine hydrochloride powder with baking soda and water and drying it, which avoids the use of explosive solvents.

6
New cards

Cocaine (Local Anesthetic Mechanism)

The interruption of action potential conduction along neural pathways accomplished by physically blocking the influx of Na+Na^+ ions through voltage-gated sodium channels into nerve cells.

7
New cards
<p>Cocaine (Central Synaptic Mechanism)</p>

Cocaine (Central Synaptic Mechanism)

The competitive inhibition of presynaptic reuptake transporters for monoamines—specifically dopamine, norepinephrine, and serotonin—which traps neurotransmitters in the synaptic cleft and potentiates their actions.

8
New cards

Cocaine Elimination Kinetics

Rapid hepatic and plasma enzymatic metabolism characterized by a half-life of approximately 1 hour1\,\text{hour}, with inactive metabolites taking approximately 3 days3\,\text{days} for complete urinary excretion after moderate use.

9
New cards

Crack Baby Syndrome

A debunked medical hypothesis asserting that prenatal cocaine exposure causes permanent developmental defects and intellectual impairment; research showed maternal malnutrition, heavy alcohol use, and polydrug abuse were the actual confounding factors.

10
New cards

Amphetamine Historical Milestones

A timeline of development beginning with isolation of active components from Ephedra (ma huang), synthetic creation by Lazăr Edeleanu (1887), methamphetamine synthesis by Nagai Nagayoshi (1893) and Akira Ogata (1919), clinical marketing of Benzedrine/Dexedrine (1930s), widespread WWII military use, and federal scheduling in the 1970s.

<p>A timeline of development beginning with isolation of active components from Ephedra (ma huang), synthetic creation by Lazăr Edeleanu (1887), methamphetamine synthesis by Nagai Nagayoshi (1893) and Akira Ogata (1919), clinical marketing of Benzedrine/Dexedrine (1930s), widespread WWII military use, and federal scheduling in the 1970s.</p>
11
New cards

Amphetamine Mechanism of Action

The promotion of monoamine neurotransmission (especially norepinephrine and dopamine) by entering presynaptic nerve terminals, displacing neurotransmitters from storage vesicles, and reversing transporter direction to stimulate direct release into the synaptic cleft.

<p>The promotion of monoamine neurotransmission (especially norepinephrine and dopamine) by entering presynaptic nerve terminals, displacing neurotransmitters from storage vesicles, and reversing transporter direction to stimulate direct release into the synaptic cleft.</p>
12
New cards

Synthetic Cathinones

Amphetamine-like stimulant derivatives naturally derived from the East African shrub khat (Catha edulis), including compounds such as mephedrone and methcathinone, often marketed as 'bath salts.'

13
New cards

Chloral Hydrate

An early synthetic sedative-hypnotic synthesized in the 19th century, famously used by Chicago bartender 'Mickey Finn' to slip into patrons' drinks to knock them unconscious for robbery.

14
New cards

Paraldehyde

A potent CNS depressant introduced clinically in 1882 with effective sedative properties and minimal respiratory depression, but whose widespread clinical use was limited by an extremely noxious taste and offensive breath odor.

15
New cards

Barbiturates

The first widely prescribed family of synthetic sedative-hypnotic depressants, used as anticonvulsants, low-dose sedatives (30–50 mg30\text{--}50\,\text{mg} of phenobarbital), and high-dose hypnotics (100–200 mg100\text{--}200\,\text{mg} of secobarbital), carrying severe risks of fatal respiratory depression.

16
New cards

Methaqualone

A sedative-hypnotic non-barbiturate synthesized in India and introduced in Germany in 1960; despite initial claims of safety, rampant abuse, suicide cases, and addiction led to its Schedule II placement in 1973 and total Schedule I prohibition by 1985.

17
New cards

Chlordiazepoxide (Librium)

The first synthesized benzodiazepine, marketed in 1960 as an anxiolytic with a significantly wider margin of safety than barbiturates when ingested without other depressants.

18
New cards

Diazepam (Valium)

A potent, lower-dose, long-acting benzodiazepine introduced in the 1970s that became the single best-selling prescription drug in the United States between 1972 and 1978.

19
New cards

Flunitrazepam (Rohypnol)

A potent benzodiazepine marketed outside the United States as a hypnotic, which became notorious in the 1990s as a date-rape agent when dissolved unnoticed into alcoholic beverages.

20
New cards

Inhalants (Pharmacological Mechanism)

Volatile solvents (such as toluene and trichloroethane) that act as positive allosteric modulators at GABAA\text{GABA}_A and glycine receptors, enhancing inhibitory post-synaptic potentials and suppressing general central nervous system excitability.

21
New cards

Nitrous Oxide

Known as 'laughing gas,' an inhalant first utilized clinically in the early 1800s that produces mild analgesia and euphoria but cannot induce safe surgical anesthesia alone without risking severe hypoxia.

22
New cards

Electroconvulsive Therapy (ECT)

A psychiatric intervention that applies electrical currents to the brain under general anesthesia and muscle relaxation to trigger controlled seizures, reserved for treatment-resistant depression and bipolar disorder.

<p>A psychiatric intervention that applies electrical currents to the brain under general anesthesia and muscle relaxation to trigger controlled seizures, reserved for treatment-resistant depression and bipolar disorder.</p>
23
New cards

DSM-5

The Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition), published by the American Psychiatric Association, which establishes standardized behavioral symptom criteria to classify mental illnesses in the absence of biological tests.

24
New cards

Neurodivergent

A framework recognizing that variations in human brain function, cognition, learning styles, and behavior represent natural diversity rather than singular pathology or a single 'right' neurological state.

25
New cards

Psychosis vs. Schizophrenia

Psychosis is an acute loss of reality contact (hallucinations/delusions) with diverse potential organic or drug etiologies, whereas schizophrenia is a chronic, lifelong psychiatric disorder diagnosed by exclusion lasting at least six months with positive, negative, and cognitive symptoms.

<p>Psychosis is an acute loss of reality contact (hallucinations/delusions) with diverse potential organic or drug etiologies, whereas schizophrenia is a chronic, lifelong psychiatric disorder diagnosed by exclusion lasting at least six months with positive, negative, and cognitive symptoms.</p>
26
New cards

Antipsychotic Drug Mechanism

The selective antagonism of post-synaptic dopamine D2D_2 receptors in mesolimbic and striatal pathways, alleviating aberrant salience of stimuli after a characteristic therapeutic latency of 10 to 14 days10\text{ to }14\,\text{days}.

27
New cards

Dopamine Receptor Supersensitivity / Rebound Psychosis

A compensatory upregulation in the number and sensitivity of dopamine receptors following long-term pharmacological antagonism, which causes excessive stimulation and severe withdrawal or rebound symptoms if medication is abruptly withdrawn.

<p>A compensatory upregulation in the number and sensitivity of dopamine receptors following long-term pharmacological antagonism, which causes excessive stimulation and severe withdrawal or rebound symptoms if medication is abruptly withdrawn.</p>
28
New cards

Agranulocytosis

A severe, life-threatening suppression of white blood cell (neutrophil) bone marrow production, representing a critical adverse hematological side effect of the atypical antipsychotic clozapine.

<p>A severe, life-threatening suppression of white blood cell (neutrophil) bone marrow production, representing a critical adverse hematological side effect of the atypical antipsychotic clozapine.</p>
29
New cards

Extrapyramidal Symptoms (EPS)

A spectrum of motor side effects produced by neuroleptic dopamine blockade in the nigrostriatal pathway, including pseudoparkinsonism (tremors, rigidity, shuffling gait), acute dystonia (spasms), and akathisia (motor restlessness).

<p>A spectrum of motor side effects produced by neuroleptic dopamine blockade in the nigrostriatal pathway, including pseudoparkinsonism (tremors, rigidity, shuffling gait), acute dystonia (spasms), and akathisia (motor restlessness).</p>
30
New cards

Tardive Dyskinesia

An often irreversible movement disorder caused by long-term neuroleptic-induced dopamine receptor supersensitivity, presenting with involuntary choreiform movements such as tongue protrusion, lip smacking, rapid blinking, and pelvic thrusting.

<p>An often irreversible movement disorder caused by long-term neuroleptic-induced dopamine receptor supersensitivity, presenting with involuntary choreiform movements such as tongue protrusion, lip smacking, rapid blinking, and pelvic thrusting.</p>
31
New cards

Major Depressive Disorder (Diagnostic Criteria)

A mood condition diagnosed when an individual presents for at least two weeks with five or more core symptoms, which must include depressed mood or anhedonia (loss of interest/pleasure), alongside changes in weight, sleep, energy, and cognition.

<p>A mood condition diagnosed when an individual presents for at least two weeks with five or more core symptoms, which must include depressed mood or anhedonia (loss of interest/pleasure), alongside changes in weight, sleep, energy, and cognition.</p>
32
New cards

Bipolar I Disorder

A psychiatric affective disorder diagnosed by the occurrence of at least one manic episode characterized by an abnormally elevated or irritable mood, grandiosity, reduced sleep need, pressured speech, and high-risk behaviors.

33
New cards

Monoamine Oxidase Inhibitors (MAOIs)

Antidepressants that inhibit the catabolic enzyme monoamine oxidase, elevating synaptic serotonin, dopamine, and norepinephrine levels, but requiring strict dietary restriction of tyramine to avoid fatal hypertensive crisis and stroke.

34
New cards

Tricyclic Antidepressants (TCAs)

A first-generation class of antidepressants discovered during research into phenothiazine antipsychotics that block the neuronal reuptake of norepinephrine, serotonin, and to a lesser extent dopamine.

35
New cards

Selective Serotonin Reuptake Inhibitors (SSRIs)

A modern class of antidepressants exemplified by fluoxetine (Prozac, introduced in 1987) that selectively inhibit presynaptic serotonin transporters, providing higher overdose safety and lower anticholinergic toxicity than TCAs.

36
New cards

Lithium Carbonate (Neurochemical Mechanism)

A mood-stabilizing monovalent cation used in bipolar disorder that increases cerebrospinal fluid GABA\text{GABA} levels, enhances presynaptic GABA\text{GABA} release, and upregulates postsynaptic GABAB\text{GABA}_B receptors to normalize neural transmission.

<p>A mood-stabilizing monovalent cation used in bipolar disorder that increases cerebrospinal fluid $$\text{GABA}$$ levels, enhances presynaptic $$\text{GABA}$$ release, and upregulates postsynaptic $$\text{GABA}_B$$ receptors to normalize neural transmission.</p>
37
New cards

Buspirone

A non-benzodiazepine anxiolytic that acts as a partial agonist at serotonin 5-HT1A5\text{-HT}_{1A} receptors and modulates dopamine receptors, managing chronic anxiety without producing significant sedation, hypnosis, or physical dependence.

38
New cards

Alcohol Fermentation Equation

The biochemical reaction catalyzed by yeast enzymes converting simple hexose sugars into ethanol and carbon dioxide: C6H12O6→2 C2H5OH+2 CO2\text{C}_6\text{H}_{12}\text{O}_6 \rightarrow 2\,\text{C}_2\text{H}_5\text{OH} + 2\,\text{CO}_2.

39
New cards

Distillation

The process of heating a fermented alcoholic solution to vaporize alcohol at a lower boiling point than water, condensing the vapors to produce distilled spirits exceeding 15%15\% alcohol by volume.

40
New cards

Standard Drink Unit

A standardized alcoholic beverage containing approximately 0.5 to 0.6 oz0.5\text{ to }0.6\,\text{oz} of pure ethanol, equivalent to 12 oz12\,\text{oz} of beer (4.5–5%4.5\text{--}5\%), 5 oz5\,\text{oz} of table wine (12%12\%), or 1.5 oz1.5\,\text{oz} of 80-proof80\text{-proof} distilled spirits (40%40\%).

<p>A standardized alcoholic beverage containing approximately $$0.5\text{ to }0.6\,\text{oz}$$ of pure ethanol, equivalent to $$12\,\text{oz}$$ of beer ($$4.5\text{--}5\%$$), $$5\,\text{oz}$$ of table wine ($$12\%$$), or $$1.5\,\text{oz}$$ of $$80\text{-proof}$$ distilled spirits ($$40\%$$).</p>
41
New cards

Alcohol Dehydrogenase (ADH)

A zinc-dependent oxidoreductase enzyme located in the gastric mucosa and liver that oxidizes ethanol into toxic acetaldehyde while reducing NAD+\text{NAD}^+ to NADH+H+\text{NADH} + \text{H}^+.

42
New cards

Aldehyde Dehydrogenase (ALDH) / Asian Flush Response

The hepatic mitochondrial enzyme converting acetaldehyde into acetate; a genetic deficiency in ALDH-2 leads to acetaldehyde buildup, elevated catecholamines, cutaneous vasodilation, tachycardia, and severe nausea.

<p>The hepatic mitochondrial enzyme converting acetaldehyde into acetate; a genetic deficiency in ALDH-2 leads to acetaldehyde buildup, elevated catecholamines, cutaneous vasodilation, tachycardia, and severe nausea.</p>
43
New cards

Ethanol Clearance Rate

The zero-order hepatic metabolic clearance of ethanol occurring at an average constant rate of 0.25 to 0.30 ounces0.25\text{ to }0.30\,\text{ounces} of pure ethanol per hour in healthy adult humans.

44
New cards

Blood Alcohol Concentration (BAC) Stages

A graded continuum of physiological effects progressing from mild disinhibition (BAC=0.02–0.03%\text{BAC} = 0.02\text{--}0.03\%), motor/speech impairment (BAC=0.10%\text{BAC} = 0.10\%), dysphoria and nausea (BAC=0.16–0.20%\text{BAC} = 0.16\text{--}0.20\%), to stupor, respiratory arrest, and coma (BAC≥0.40%\text{BAC} \ge 0.40\%).

<p>A graded continuum of physiological effects progressing from mild disinhibition ($$\text{BAC} = 0.02\text{--}0.03\%$$), motor/speech impairment ($$\text{BAC} = 0.10\%$$), dysphoria and nausea ($$\text{BAC} = 0.16\text{--}0.20\%$$), to stupor, respiratory arrest, and coma ($$\text{BAC} \ge 0.40\%$$).</p>
45
New cards

Alcohol Myopia

A cognitive impairment produced by ethanol intoxication where perception and attention are restricted strictly to immediate, salient situational cues while long-term consequences and risks are ignored.

46
New cards

Fetal Alcohol Syndrome (FAS)

A congenital disorder resulting from maternal alcohol intake during pregnancy, clinically identified by microcephaly, small palpebral fissures, a smooth philtrum, a thin upper lip, micrognathia, and irreversible central nervous system dysfunction.

<p>A congenital disorder resulting from maternal alcohol intake during pregnancy, clinically identified by microcephaly, small palpebral fissures, a smooth philtrum, a thin upper lip, micrognathia, and irreversible central nervous system dysfunction.</p>
47
New cards

Alcohol Withdrawal Syndrome Stages

A progressive physical withdrawal sequence consisting of autonomic hyperactivity and tremors (Stage 1), vivid hallucinations (Stage 2), global disorientation and delirium (Stage 3), and generalized tonic-clonic seizures (Stage 4).

48
New cards

Nicotine (Cholinergic Receptor Mechanism)

The biphasic stimulation followed by desensitizing depolarization block of nicotinic acetylcholine receptors (nAChRs\text{nAChRs}), triggering the downstream exocytosis of dopamine, epinephrine, and norepinephrine.

<p>The biphasic stimulation followed by desensitizing depolarization block of nicotinic acetylcholine receptors ($$\text{nAChRs}$$), triggering the downstream exocytosis of dopamine, epinephrine, and norepinephrine.</p>
49
New cards

Nicotine Acute Lethal Dose

The toxic quantity of pure nicotine sufficient to trigger fatal respiratory neuromuscular paralysis in humans, established at approximately 60 mg60\,\text{mg} (equivalent to the nicotine contained in two typical cigars).

50
New cards

Sidestream Smoke

The unfiltered, hazardous smoke that wafts directly into ambient air from the smoldering tip of a cigarette, containing significantly higher concentrations of carcinogens than inhaled mainstream smoke.

51
New cards

Caffeine (Adenosine Antagonism Mechanism)

The primary wakefulness-promoting action of 1,3,7-trimethylxanthine achieved by competitively blocking inhibitory A1A_1 and A2AA_{2A} adenosine receptors across the brain, disinhibiting the release of excitatory neurotransmitters.

<p>The primary wakefulness-promoting action of 1,3,7-trimethylxanthine achieved by competitively blocking inhibitory $$A_1$$ and $$A_{2A}$$ adenosine receptors across the brain, disinhibiting the release of excitatory neurotransmitters.</p>
52
New cards

Theophylline

A dimethylxanthine present in tea leaves (Camellia sinensis) that exerts potent bronchodilatory and smooth muscle-relaxing effects, used clinically in the management of asthma.

53
New cards

Theobromine

A xanthine alkaloid found predominantly in cacao beans (Theobroma cacao) and chocolate, supplying approximately 200 mg200\,\text{mg} per cup of cocoa with substantially weaker CNS stimulant activity than caffeine.

54
New cards

Caffeine Withdrawal Headache

The hallmark physical dependence symptom following caffeine cessation caused by cerebral rebound vasodilation, emerging on average 18 to 19 hours18\text{ to }19\,\text{hours} after the last dose.

55
New cards

Caffeine Acute Lethal Threshold

The quantity of caffeine estimated to produce fatal tonic-clonic convulsions and cardiovascular/respiratory arrest in humans, approximately 10 grams10\,\text{grams} (equivalent to consuming roughly 100 cups100\,\text{cups} of brewed coffee).